Stereotaxis Announces Definitive Agreement to Acquire Robocath
Rhea-AI Summary
Stereotaxis (NYSE: STXS) announced a definitive agreement to acquire Robocath on April 15, 2026, combining magnetic navigation and mechanical robotics to target electrophysiology, interventional cardiology and neurointerventions.
The deal includes an upfront payment of $20 million, contingent payments up to $25 million, expected mid-2026 close, and estimated $2 million first-year revenue with breakeven by year three.
AI-generated analysis. Not financial advice.
Positive
- $20M upfront consideration
- Up to $25M contingent milestone payments
- Robocath has 15 commercial R-One+ systems installed globally
- Estimated $2M revenue in first post-acquisition year
- Targeted breakeven by the third year post-acquisition
- Planned U.S. and EU regulatory submissions within 2 years
Negative
- Consideration payable in cash or stock may cause share dilution
- Contingent payments raise total acquisition cost up to $45M
- Acquisition closing is subject to customary conditions; timing risk to mid-2026
- Near-term low revenue contribution
News Market Reaction – STXS
On the day this news was published, STXS declined 0.99%, reflecting a mild negative market reaction. Argus tracked a peak move of +4.6% during that session. Argus tracked a trough of -12.8% from its starting point during tracking. Our momentum scanner triggered 8 alerts that day, indicating moderate trading interest and price volatility. This price movement removed approximately $2M from the company's valuation, bringing the market cap to $197.88M at that time.
Data tracked by StockTitan Argus on the day of publication.
Key Figures
Market Reality Check
Peers on Argus
STXS gained 5.73% on the acquisition while key peers like OSUR, MBOT, INFU, and NYXH show moderate gains but sector momentum scanners only flagged one other name, suggesting a largely stock-specific move.
Previous Acquisition Reports
| Date | Event | Sentiment | Move | Catalyst |
|---|---|---|---|---|
| May 13 | Platform expansion deal | Positive | -3.2% | Definitive agreement to acquire Access Point Technologies EP for EP catheters. |
Prior acquisition news in May 2024 saw a negative -3.24% reaction despite strategic rationale, contrasting with today’s positive move.
Over the past two years, Stereotaxis has used acquisitions to expand its endovascular robotics platform. In May 2024, it agreed to acquire Access Point Technologies EP, adding electrophysiology catheter development and manufacturing, but shares fell 3.24% over the next day. Today’s Robocath deal similarly targets technology breadth and commercial synergies in endovascular procedures, but the pre-news setup and initial price response differ from that earlier acquisition.
Historical Comparison
In the past, STXS’s only tracked acquisition headline saw shares fall 3.24%. Today’s 5.73% gain on the Robocath deal marks a stronger and opposite initial reaction.
Acquisition strategy appears to broaden the platform from EP catheters (APT) into mechanical robotics for interventional cardiology and neurointerventions with Robocath.
Regulatory & Risk Context
An effective S-3 shelf filed on 2026-03-13 registers up to $100,000,000 of securities, including a $50,000,000 at-the-market program, with no reported usage yet and expiration on 2029-03-13.
Market Pulse Summary
This announcement details a definitive agreement to acquire Robocath, adding mechanical robotics for interventional cardiology and neurointerventions and an expected $2 million in year-one revenue with breakeven targeted by year three. It builds on Stereotaxis’ broader strategy of expanding its endovascular robotics platform. Investors may track regulatory submissions over the next two years, commercialization progress of the next‑generation system, and any use of the active $100,000,000 shelf when assessing execution risk.
Key Terms
percutaneous coronary interventions medical
endovascular procedures medical
neurointerventions medical
angioplasty medical
meta-analysis medical
remote interventions medical
forward-looking statements regulatory
AI-generated analysis. Not financial advice.
ST. LOUIS and ROUEN, France, April 15, 2026 (GLOBE NEWSWIRE) -- Stereotaxis (NYSE: STXS), a pioneer and global leader in surgical robotics for minimally invasive endovascular intervention, today announced that it has entered into a definitive agreement to acquire Robocath, a venture-backed innovator of robotic technologies for interventional cardiology and neurointerventions.
This acquisition significantly strengthens Stereotaxis’ position as a leading platform for the full spectrum of endovascular procedures, combining complementary technologies to deliver next-generation fully-integrated robotic solutions for electrophysiology, interventional cardiology and neurointerventions.
“Robocath represents a highly strategic addition to Stereotaxis, amplifying and accelerating our strategy as the leading robotic platform for the broad spectrum of endovascular procedures,” said David Fischel, Stereotaxis Chairman and CEO. “By combining our complementary robotic mechanisms, we are creating a uniquely capable platform that expands our reach across interventional medicine. This transaction accelerates our strategy, enhances our technological leadership, provides attractive commercial synergies, opens new avenues for growth, and supports other strategic opportunities being pursued by Stereotaxis.”
Robocath, headquartered in Rouen, France, has developed the most advanced mechanical robotic technology for interventional cardiology and neurointerventions. Its flagship R-One+™ system is the only commercially available robotic solution currently available for percutaneous coronary interventions in Europe, with fifteen commercial R-One+ systems installed globally. Robocath is developing a next-generation system, designed to enable simultaneous manipulation of up to five interventional devices. Initial first-in-human procedures were recently successfully completed in France. Robocath’s differentiated technologies are supported by a robust intellectual property portfolio.
“For over fifteen years, we have been committed to pioneering the most sophisticated plug-and-play bionic robotic technology for endovascular procedures,” said Philippe Bencteux, Robocath Founder and CEO. “Joining Stereotaxis provides the scale, complementary technologies, and strategic alignment needed to accelerate our development and expand our impact. We believe this combination will unlock significant opportunities in rapidly growing markets, which are becoming increasingly receptive to robotics.”
The combination of Stereotaxis’ magnetic navigation technology and Robocath’s mechanical robotic system creates a highly differentiated fully-robotic solution for endovascular surgery. Stereotaxis uses precise computer-controlled magnetic fields to enable unprecedented navigation of the distal tip of interventional devices, while Robocath’s platform provides multi-device control at the bedside. There is defined value to each technology on a standalone basis. Together, these technologies offer a powerful and synergistic approach to improving procedural precision, efficiency, and outcomes.
Stereotaxis plans to accelerate the development of Robocath’s next generation system and pursue regulatory submissions in the United States and Europe within the next two years. Stereotaxis will enhance Robocath’s system with existing proprietary hardware and software embedded within GenesisX, Synchrony and SynX, enabling advanced functionality including operating room integration, automation, and remote procedures. The combined platform will integrate the robotic systems of Robocath and Stereotaxis, to offer a seamless joint solution in interventional cardiology and neurointerventions. Future developments are expected to expand applications into Electrophysiology.
Stereotaxis estimates that Robocath will contribute approximately
The transaction consideration includes an upfront payment of
“We are delighted to welcome the accomplished Robocath team to Stereotaxis,” added David Fischel. “This acquisition is a reflection of our commitment to technological leadership across endovascular robotics, with continued investment in significant innovations that improve access, efficiency, and outcomes of minimally-invasive cardiovascular and neurovascular therapies.”
Conference Call and Webcast
Stereotaxis will discuss the acquisition and provide an opportunity for Q&A during an investor conference call and webcast today, April 15, 2026, at 9:00 a.m. Eastern Time. To access the conference call, dial 1-800-715-9871 (US and Canada) or 1-646-307-1963 (International) and give the participant pass code 4382524. To access the live and replay webcast, please visit the investor relations section of the Stereotaxis website at www.Stereotaxis.com.
About Stereotaxis
Stereotaxis (NYSE: STXS) is a pioneer and global leader in innovative surgical robotics for minimally invasive endovascular intervention. Its mission is the discovery, development and delivery of robotic systems, instruments, and information solutions for the interventional laboratory. These innovations help physicians provide unsurpassed patient care with robotic precision and safety, expand access to minimally invasive therapy, and enhance the productivity, connectivity, and intelligence in the operating room. Stereotaxis technology has been used to treat over 150,000 patients across the United States, Europe, Asia, and elsewhere. For more information, please visit www.stereotaxis.com.
About Robocath
Founded in 2009 by Philippe Bencteux, MD, Robocath designs, develops and markets smart robotic solutions to treat cardiovascular and neurovascular diseases. Robocath robotic solutions integrate a unique bionic technology that optimizes the safety of robotic-assisted coronary angioplasty. Robocath’s robotic solutions are designed to operate with precision and perform accurate movements, creating better interventional conditions. Thanks to their open architecture, they are compatible with market-leading devices and catheter laboratories. Robocath has obtained CE and NMPA certifications for its first robotic solution. Several multicenter clinical studies have been conducted, and a meta-analysis has demonstrated R-One’s safety and efficacy as it achieved more than
This press release includes statements that may constitute "forward-looking" statements, usually containing the words "believe”, "estimate”, "project”, "expect" or similar expressions. These forward-looking statements include without limitation statements regarding the proposed acquisition, its timing and its consummation, the anticipated financial performance of Stereotaxis and Robocath related thereto, including the anticipated closing of, and benefits expected from, the proposed acquisition, potential strategic implications as a result of the proposed acquisition, and the potential for achievement of the regulatory and commercial milestones that would trigger contingent payments in the transaction. Forward-looking statements inherently involve risks and uncertainties that could cause actual results to differ materially. Factors that would cause or contribute to such differences include, but are not limited to, uncertainties involving the following: the potential timing of the consummation of the proposed acquisition and the ability of the parties to consummate the proposed transaction; the satisfaction of the conditions precedent to consummation of the proposed transaction, any litigation related to the proposed transaction; disruption of Robocath’s or Stereotaxis’s current plans and operations as a result of the proposed transaction; the ability of Robocath or Stereotaxis to retain and hire key personnel; competitive responses to the proposed transaction; unexpected costs, charges or expenses resulting from the proposed transaction; the ability of Stereotaxis to successfully integrate Robocath’s operations, and continue the commercialization, development and sales of Robocath’s products and services; the ability of Stereotaxis to implement its plans, forecasts and other expectations with respect to Robocath’s business after the completion of the proposed transaction and realize additional opportunities for growth and innovation; the ability of Stereotaxis to realize the anticipated benefits from the proposed transaction in the anticipated amounts or within the anticipated timeframes or at all; the ability to maintain relationships with Stereotaxis’s and Robocath’s respective employees, customers, other business partners and governmental authorities; and the other risks discussed in the Company's periodic and other filings with the Securities and Exchange Commission. Additional risks and uncertainties that could affect our financial results are included under the captions "Risk Factors" and "Management's Discussion and Analysis of Financial Condition and Results of Operations" in our Annual Report on Form 10-K filed with the SEC on March 12, 2026, which is available on our website at https://ir.stereotaxis.com and on the SEC’s website at www.sec.gov. Additional information will also be set forth in other filings that we make with the SEC from time to time. All forward-looking statements in this press release are based on information available to us as of the date hereof, and we do not assume any obligation to update the forward-looking statements provided to reflect events that occur or circumstances that exist after the date on which they were made. There can be no assurance that the Company will recognize revenue related to its purchase orders and other commitments because some of these purchase orders and other commitments are subject to contingencies that are outside of the Company's control and may be revised, modified, delayed, or canceled.
Company Contacts:
David L. Fischel
Chairman and Chief Executive Officer
Kimberly R. Peery
Chief Financial Officer
314-678-6100
Investors@Stereotaxis.com
